TrialAdvances in therapy2016

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.

James G Krueger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.